☰

Richard D. Egleton - Publications

Affiliations: 
Marshall University, Huntington, WV, United States 
Area:
blood-brain barrier, drug delivery
Tree Info Grants Similar researchers PubMed Report error

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Davis TP, Abbruscato TJ, Egleton RD. Peptides at the blood brain barrier: Knowing me knowing you. Peptides. PMID 25937599 DOI: 10.1016/j.peptides.2015.04.020  0.595
2014 Egleton RD, Abbruscato T. Drug abuse and the neurovascular unit. Advances in Pharmacology (San Diego, Calif.). 71: 451-80. PMID 25307226 DOI: 10.1016/bs.apha.2014.06.019  0.364
2013 Egleton RD, Witt KA, Davis TP. Opioid Peptides Handbook of Biologically Active Peptides. 1696-1701. DOI: 10.1016/B978-0-12-385095-9.00232-3  0.682
2012 Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, Shah YH, Shiflett BS, Marcelo AJ, Proper NA, Hardman WE, Egleton RD, Chen YC, Mangiarua EI, Dasgupta P. MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis. 15: 99-114. PMID 22198237 DOI: 10.1007/S10456-011-9246-9  0.762
2012 Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, Shah YH, Shiflett BS, Marcelo AJ, Proper NA, Hardman WE, Egleton RD, Chen YC, Mangiarua EI, Dasgupta P. Erratum to: MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway Angiogenesis. 15: 331-331. DOI: 10.1007/S10456-012-9258-0  0.741
2011 Dom AM, Buckley AW, Brown KC, Egleton RD, Marcelo AJ, Proper NA, Weller DE, Shah YH, Lau JK, Dasgupta P. The α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells. Investigative Ophthalmology & Visual Science. 52: 4428-38. PMID 20554619 DOI: 10.1167/Iovs.10-5461  0.76
2009 Egleton RD, Brown KC, Dasgupta P. Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. Pharmacology & Therapeutics. 121: 205-23. PMID 19063919 DOI: 10.1016/j.pharmthera.2008.10.007  0.307
2008 Campos CR, Ocheltree SM, Hom S, Egleton RD, Davis TP. Nociceptive inhibition prevents inflammatory pain induced changes in the blood-brain barrier. Brain Research. 1221: 6-13. PMID 18554577 DOI: 10.1016/J.Brainres.2008.05.013  0.815
2008 Hawkins BT, Egleton RD. Pathophysiology of the blood-brain barrier: animal models and methods. Current Topics in Developmental Biology. 80: 277-309. PMID 17950377 DOI: 10.1016/S0070-2153(07)80007-X  0.82
2007 McCaffrey G, Staatz WD, Quigley CA, Nametz N, Seelbach MJ, Campos CR, Brooks TA, Egleton RD, Davis TP. Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. Journal of Neurochemistry. 103: 2540-55. PMID 17931362 DOI: 10.1111/J.1471-4159.2007.04943.X  0.79
2007 Seelbach MJ, Brooks TA, Egleton RD, Davis TP. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. Journal of Neurochemistry. 102: 1677-90. PMID 17697052 DOI: 10.1111/J.1471-4159.2007.04644.X  0.825
2007 Hom S, Fleegal MA, Egleton RD, Campos CR, Hawkins BT, Davis TP. Comparative changes in the blood-brain barrier and cerebral infarction of SHR and WKY rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 292: R1881-92. PMID 17234953 DOI: 10.1152/Ajpregu.00761.2005  0.788
2007 Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 50: 202-11. PMID 17143608 DOI: 10.1007/s00125-006-0485-z  0.792
2007 Hawkins BT, Ocheltree SM, Norwood KM, Egleton RD. Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats. Neuroscience Letters. 411: 1-5. PMID 17110033 DOI: 10.1016/j.neulet.2006.09.010  0.818
2006 Brooks TA, Ocheltree SM, Seelbach MJ, Charles RA, Nametz N, Egleton RD, Davis TP. Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Research. 1120: 172-82. PMID 17007822 DOI: 10.1016/J.Brainres.2006.08.085  0.821
2006 Hawkins BT, Egleton RD. Fluorescence imaging of blood-brain barrier disruption. Journal of Neuroscience Methods. 151: 262-7. PMID 16181683 DOI: 10.1016/j.jneumeth.2005.08.006  0.809
2006 Egleton RD, Witt KA, Davis TP. Opiate Peptides And The Blood-Brain Barrier Handbook of Biologically Active Peptides. 1429-1434. DOI: 10.1016/B978-012369442-3/50202-6  0.771
2005 Dhanasekaran M, Palian MM, Alves I, Yeomans L, Keyari CM, Davis P, Bilsky EJ, Egleton RD, Yamamura HI, Jacobsen NE, Tollin G, Hruby VJ, Porreca F, Polt R. Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers. Journal of the American Chemical Society. 127: 5435-48. PMID 15826181 DOI: 10.1021/Ja0432158  0.301
2005 Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. American Journal of Physiology. Heart and Circulatory Physiology. 289: H738-43. PMID 15792985 DOI: 10.1152/Ajpheart.01288.2004  0.824
2005 Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 44-53. PMID 15717056 DOI: 10.1602/neurorx.2.1.44  0.625
2005 Hawkins BT, Egleton RD, Davis TP. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. American Journal of Physiology. Heart and Circulatory Physiology. 289: H212-9. PMID 15708958 DOI: 10.1152/ajpheart.01210.2004  0.808
2005 Egleton RD, Bilsky EJ, Tollin G, Dhanasekaran M, Lowery J, Alves I, Davis P, Porreca F, Yamamura HI, Yeomans L, Keyari CM, Polt R. Biousian glycopeptides penetrate the blood-brain barrier Tetrahedron Asymmetry. 16: 65-75. DOI: 10.1016/J.Tetasy.2004.11.038  0.5
2004 Hawkins BT, Abbruscato TJ, Egleton RD, Brown RC, Huber JD, Campos CR, Davis TP. Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Research. 1027: 48-58. PMID 15494156 DOI: 10.1016/J.Brainres.2004.08.043  0.806
2004 Brown RC, Egleton RD, Davis TP. Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. Brain Research. 1014: 221-7. PMID 15213006 DOI: 10.1016/j.brainres.2004.04.034  0.673
2004 Elmagbari NO, Egleton RD, Palian MM, Lowery JJ, Schmid WR, Davis P, Navratilova E, Dhanasekaran M, Keyari CM, Yamamura HI, Porreca F, Hruby VJ, Polt R, Bilsky EJ. Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. The Journal of Pharmacology and Experimental Therapeutics. 311: 290-7. PMID 15166257 DOI: 10.1124/Jpet.104.069393  0.399
2004 Brown RC, Mark KS, Egleton RD, Davis TP. Protection against hypoxia-induced blood-brain barrier disruption: changes in intracellular calcium. American Journal of Physiology. Cell Physiology. 286: C1045-52. PMID 15075203 DOI: 10.1152/Ajpcell.00360.2003  0.774
2003 Huber JD, Campos CR, Egleton RD, Witt K, Guo L, Roberts MJ, Bentley MD, Davis TP. Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile. Journal of Pharmaceutical Sciences. 92: 1377-85. PMID 12820142 DOI: 10.1002/Jps.10406  0.765
2003 Egleton RD, Campos CC, Huber JD, Brown RC, Davis TP. Differential effects of diabetes on rat choroid plexus ion transporter expression. Diabetes. 52: 1496-501. PMID 12765962 DOI: 10.2337/Diabetes.52.6.1496  0.57
2003 Brown RC, Mark KS, Egleton RD, Huber JD, Burroughs AR, Davis TP. Protection against hypoxia-induced increase in blood-brain barrier permeability: role of tight junction proteins and NFkappaB. Journal of Cell Science. 116: 693-700. PMID 12538770 DOI: 10.1242/Jcs.00264  0.809
2003 Egleton RD, Witt KA, Davis TP. Peptides and the Blood-Brain Barrier: Enhancing Peptide Bioavailability to the Brain Blood-Spinal Cord and Brain Barriers in Health and Disease. 107-115. DOI: 10.1016/B978-012639011-7/50015-2  0.764
2002 Witt KA, Huber JD, Egleton RD, Davis TP. Pluronic p85 block copolymer enhances opioid peptide analgesia. The Journal of Pharmacology and Experimental Therapeutics. 303: 760-7. PMID 12388663 DOI: 10.1124/Jpet.102.039545  0.716
2002 Huber JD, Hau VS, Borg L, Campos CR, Egleton RD, Davis TP. Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. American Journal of Physiology. Heart and Circulatory Physiology. 283: H1531-7. PMID 12234806 DOI: 10.1152/Ajpheart.00027.2002  0.816
2001 Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides. 22: 2329-43. PMID 11786210 DOI: 10.1016/S0196-9781(01)00537-X  0.761
2001 Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends in Neurosciences. 24: 719-25. PMID 11718877 DOI: 10.1016/S0166-2236(00)02004-X  0.672
2001 Egleton RD, Mitchell SA, Huber JD, Palian MM, Polt R, Davis TP. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. The Journal of Pharmacology and Experimental Therapeutics. 299: 967-72. PMID 11714884  0.611
2001 Witt KA, Huber JD, Egleton RD, Roberts MJ, Bentley MD, Guo L, Wei H, Yamamura HI, Davis TP. Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [D-Pen2, D-Pen5]-enkephalin (DPDPE). The Journal of Pharmacology and Experimental Therapeutics. 298: 848-56. PMID 11454951  0.746
2001 Huber JD, Witt KA, Hom S, Egleton RD, Mark KS, Davis TP. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. American Journal of Physiology. Heart and Circulatory Physiology. 280: H1241-8. PMID 11179069 DOI: 10.1152/Ajpheart.2001.280.3.H1241  0.808
2001 Hom S, Egleton RD, Huber JD, Davis TP. Effect of reduced flow on blood-brain barrier transport systems. Brain Research. 890: 38-48. PMID 11164767 DOI: 10.1016/S0006-8993(00)03027-4  0.747
2000 Witt KA, Huber JD, Egleton RD, Davis TP. Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. The Journal of Pharmacology and Experimental Therapeutics. 295: 972-8. PMID 11082431  0.735
2000 Egleton RD, Mitchell SA, Huber JD, Janders J, Stropova D, Polt R, Yamamura HI, Hruby VJ, Davis TP. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Research. 881: 37-46. PMID 11033091 DOI: 10.1016/S0006-8993(00)02794-3  0.643
2000 Bilsky EJ, Egleton RD, Mitchell SA, Palian MM, Davis P, Huber JD, Jones H, Yamamura HI, Janders J, Davis TP, Porreca F, Hruby VJ, Polt R. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. Journal of Medicinal Chemistry. 43: 2586-90. PMID 10891118 DOI: 10.1021/Jm000077Y  0.672
2000 Witt KA, Slate CA, Egleton RD, Huber JD, Yamamura HI, Hruby VJ, Davis TP. Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin. Journal of Neurochemistry. 75: 424-35. PMID 10854288 DOI: 10.1046/J.1471-4159.2000.0750424.X  0.721
1999 Gentry CL, Egleton RD, Gillespie T, Abbruscato TJ, Bechowski HB, Hruby VJ, Davis TP. The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides. 20: 1229-38. PMID 10573295 DOI: 10.1016/S0196-9781(99)00127-8  0.66
1999 Egleton RD, Davis TP. Transport of the delta-opioid receptor agonist [D-penicillamine2,5] enkephalin across the blood-brain barrier involves transcytosis1. Journal of Pharmaceutical Sciences. 88: 392-7. PMID 10187748 DOI: 10.1021/js980410+  0.678
1998 Egleton RD, Abbruscato TJ, Thomas SA, Davis TP. Transport of opioid peptides into the central nervous system. Journal of Pharmaceutical Sciences. 87: 1433-9. PMID 9811502 DOI: 10.1021/js980062b  0.619
1998 Egleton RD, Thomas SA, Davis TP. Opioid peptide prodrugs: In vitro blood-brain barrier permeability and conversion rates Proceedings of the Controlled Release Society. 531-532.  0.365
1997 Egleton RD, Davis TP. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides. 18: 1431-9. PMID 9392847 DOI: 10.1016/S0196-9781(97)00242-8  0.659
Show low-probability matches.